General Information of Drug Off-Target (DOT) (ID: OTOKUXUH)

DOT Name Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10)
Synonyms ADAM 10; EC 3.4.24.81; CDw156; Kuzbanian protein homolog; Mammalian disintegrin-metalloprotease; CD antigen CD156c
Gene Name ADAM10
Related Disease
Reticulate acropigmentation of Kitamura ( )
UniProt ID
ADA10_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
6BDZ; 6BE6; 8ESV
EC Number
3.4.24.81
Pfam ID
PF21299 ; PF00200 ; PF13574
Sequence
MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFL
RLDFHAHGRHFNLRMKRDTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVI
DGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSVIYHEDDINYPHKYGPQGGCADHSVFE
RMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHLFFKYYGTRE
AVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKF
LELNSEQNHDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNT
GIITVQNYGSHVPPKVSHITFAHEVGHNFGSPHDSGTECTPGESKNLGQKENGNYIMYAR
ATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGNGMVEQGEECDCGYSDQCK
DECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGFT
ALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMK
KMDPSTCASTGSVQWSRHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKA
IFSPELYENIAEWIVAHWWAVLLMGIALIMLMAGFIKICSVHTPSSNPKLPPPKPLPGTL
KRRRPPQPIQQPQRQRPRESYQMGHMRR
Function
Transmembrane metalloprotease which mediates the ectodomain shedding of a myriad of transmembrane proteins, including adhesion proteins, growth factor precursors and cytokines being essential for development and tissue homeostasis. Associates with six members of the tetraspanin superfamily TspanC8 which regulate its exit from the endoplasmic reticulum and its substrate selectivity. Cleaves the membrane-bound precursor of TNF-alpha at '76-Ala-|-Val-77' to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including heparin-binding epidermal growth-like factor, ephrin-A2, CD44, CDH2 and for constitutive and regulated alpha-secretase cleavage of amyloid precursor protein (APP). Contributes to the normal cleavage of the cellular prion protein. Involved in the cleavage of the adhesion molecule L1 at the cell surface and in released membrane vesicles, suggesting a vesicle-based protease activity. Controls also the proteolytic processing of Notch and mediates lateral inhibition during neurogenesis. Responsible for the FasL ectodomain shedding and for the generation of the remnant ADAM10-processed FasL (FasL APL) transmembrane form. Also cleaves the ectodomain of the integral membrane proteins CORIN and ITM2B. Mediates the proteolytic cleavage of LAG3, leading to release the secreted form of LAG3. Mediates the proteolytic cleavage of IL6R and IL11RA, leading to the release of secreted forms of IL6R and IL11RA. Enhances the cleavage of CHL1 by BACE1. Cleaves NRCAM. Cleaves TREM2, resulting in shedding of the TREM2 ectodomain. Involved in the development and maturation of glomerular and coronary vasculature. During development of the cochlear organ of Corti, promotes pillar cell separation by forming a ternary complex with CADH1 and EPHA4 and cleaving CADH1 at adherens junctions. May regulate the EFNA5-EPHA3 signaling. Regulates leukocyte transmigration as a sheddase for the adherens junction protein VE-cadherin/CDH5 in endothelial cells ; (Microbial infection) Promotes the cytotoxic activity of S.aureus hly by binding to the toxin at zonula adherens and promoting formation of toxin pores.
Tissue Specificity Expressed in the brain (at protein level) . Expressed in spleen, lymph node, thymus, peripheral blood leukocyte, bone marrow, cartilage, chondrocytes and fetal liver .
KEGG Pathway
Efferocytosis (hsa04148 )
Alzheimer disease (hsa05010 )
Epithelial cell sig.ling in Helicobacter pylori infection (hsa05120 )
Reactome Pathway
Degradation of the extracellular matrix (R-HSA-1474228 )
Signaling by EGFR (R-HSA-177929 )
Activated NOTCH1 Transmits Signal to the Nucleus (R-HSA-2122948 )
Constitutive Signaling by NOTCH1 PEST Domain Mutants (R-HSA-2644606 )
Constitutive Signaling by NOTCH1 t(7 (R-HSA-2660826 )
Constitutive Signaling by NOTCH1 HD Domain Mutants (R-HSA-2691232 )
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants (R-HSA-2894862 )
NOTCH2 Activation and Transmission of Signal to the Nucleus (R-HSA-2979096 )
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) (R-HSA-381426 )
EPH-ephrin mediated repulsion of cells (R-HSA-3928665 )
Neutrophil degranulation (R-HSA-6798695 )
Post-translational protein phosphorylation (R-HSA-8957275 )
NOTCH3 Activation and Transmission of Signal to the Nucleus (R-HSA-9013507 )
NOTCH4 Activation and Transmission of Signal to the Nucleus (R-HSA-9013700 )
Amyloid fiber formation (R-HSA-977225 )
M1580_K2555) Translocation Mutant (9)(NOTCH1 )
Collagen degradation (R-HSA-1442490 )
BioCyc Pathway
MetaCyc:ENSG00000137845-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Reticulate acropigmentation of Kitamura DISOE459 Strong Autosomal dominant [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Cisplatin DMRHGI9 Approved Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) affects the response to substance of Cisplatin. [13]
------------------------------------------------------------------------------------
10 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin decreases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [2]
Tretinoin DM49DUI Approved Tretinoin increases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [3]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [4]
Doxorubicin DMVP5YE Approved Doxorubicin decreases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [5]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [6]
Bortezomib DMNO38U Approved Bortezomib decreases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [7]
Enzalutamide DMGL19D Approved Enzalutamide affects the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [8]
Isoflavone DM7U58J Phase 4 Isoflavone increases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [9]
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [11]
Phorbol 12,13-butyrate DMZWTY7 Investigative Phorbol 12,13-butyrate increases the expression of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Drug(s)
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene decreases the methylation of Disintegrin and metalloproteinase domain-containing protein 10 (ADAM10). [10]
------------------------------------------------------------------------------------

References

1 Whole-exome sequencing identifies ADAM10 mutations as a cause of reticulate acropigmentation of Kitamura, a clinical entity distinct from Dowling-Degos disease. Hum Mol Genet. 2013 Sep 1;22(17):3524-33. doi: 10.1093/hmg/ddt207. Epub 2013 May 10.
2 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
3 Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J. 2005 Sep;19(11):1522-4. doi: 10.1096/fj.04-3619fje. Epub 2005 Jun 21.
4 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
5 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
6 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
7 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
8 NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
9 Soy isoflavones exert differential effects on androgen responsive genes in LNCaP human prostate cancer cells. J Nutr. 2007 Apr;137(4):964-72.
10 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
11 Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
12 Regulation of secretases by all-trans-retinoic acid. FEBS J. 2009 May;276(9):2645-55. doi: 10.1111/j.1742-4658.2009.06992.x. Epub 2009 Mar 25.
13 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.